OPERATING SEGMENT AND GEOGRAPHIC INFORMATION (Details) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($) operating_segments	Jun. 30, 2014 USD ($)	Dec. 31, 2014 USD ($)
Segment Reporting [Abstract]
Number of operating segments | operating_segments			2
Segment Reporting Information [Line Items]
Net Sales	$ 7,040	$ 6,764	$ 13,553	$ 13,015
Gross Profit	2,872	2,393	5,846	4,887
Net Loss before Taxes	(3,233)	(3,901)	(6,228)	(7,572)
Income Tax Expense (Benefit)	42	(8)	88	497
NET LOSS	(3,275)	(3,893)	(6,316)	(8,069)	$ (13,942)
Depreciation/Amortization	558	488	1,111	981
Interest Expense, net	186	146	376	328
Total Assets	31,409	31,091	$ 31,409	31,091	$ 30,006
Percent of revenue from countries not separately disclosed (more than)			5.00%
United States
Segment Reporting Information [Line Items]
Net Sales	$ 5,897	4,870	$ 11,405	9,633
Long-lived asset percentage held in a specific location	99.00%		99.00%
Italy
Segment Reporting Information [Line Items]
Net Sales	$ 193	337	$ 370	722
All Other Countries
Segment Reporting Information [Line Items]
Net Sales	950	1,557	1,778	2,660
Operating Segments | Laboratory Services
Segment Reporting Information [Line Items]
Net Sales	4,839	3,843	9,710	7,531
Gross Profit	2,634	1,490	5,330	3,122
Net Loss before Taxes	(2,167)	(3,277)	(4,277)	(6,261)
Income Tax Expense (Benefit)	40	40	81	549
NET LOSS	(2,207)	(3,317)	(4,358)	(6,810)
Depreciation/Amortization	517	438	1,024	878
Interest Expense, net	131	83	273	190
Total Assets	25,870	23,370	25,870	23,370
Operating Segments | Genetic Assays and Platforms
Segment Reporting Information [Line Items]
Net Sales	2,201	2,921	3,843	5,484
Gross Profit	238	903	516	1,765
Net Loss before Taxes	(1,066)	(624)	(1,951)	(1,311)
Income Tax Expense (Benefit)	2	(48)	7	(52)
NET LOSS	(1,068)	(576)	(1,958)	(1,259)
Depreciation/Amortization	41	50	87	103
Interest Expense, net	55	63	103	138
Total Assets	$ 5,539	$ 7,721	$ 5,539	$ 7,721